Leflunomide-Mediated Immunomodulation Inhibits Lesion Progression in a Vitiligo Mouse Model
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146787 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Fang Miao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Renmin Hospital of Wuhan University, Wuhan 430060, China. Hauptthemen laut MEDLINE: Vitiligo, Leflunomide, Immunomodulation. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Autoimmune CD8+ T cell-driven melanocyte destruction constitutes a key pathogenic mechanism in the development of vitiligo. Therefore, the pharmacological inhibition of CD8+ T cell effector functions and skin trafficking is a clinically viable therapeutic strategy. This study investigates leflunomide (LEF), an immunomodulatory drug with established safety in autoimmune diseases, for its therapeutic potential in a tyrosine-related protein (TRP) 2-180-induced vitiligo mouse model. Through flow cytometry, immunofluorescence, ELISA, and histopathological analyses, we systematically evaluated LEF’s effects on T cell regulation, chemokine expression, and cytokine profiles. Key findings demonstrated that LEF (20 mg/kg/day) significantly attenuated depigmentation by reducing CD8+ T cell infiltration and suppressing the IFN-γ-driven expression of CXCL9/10. Furthermore, LEF restored CD4+/CD8+ T cell homeostasis and rebalanced pro-inflammatory (IFN-γ, TNF-α, IL-2) and anti-inflammatory (IL-4, IL-10) cytokines, inducing a shift from Th1 to Th2. These results position LEF as an effective immunomodulator that disrupts the IFN-γ-CXCL9/10 axis and re-establishes immune balance, offering a promising repurposing strategy for halting vitiligo progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
ORCID-Profile: Ying Shi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
Zitieren
APA
Miao, F., Li, X., Zhao, L., Zhang, S., Geng, M., Ye, C., Shi, Y., & Lei, T. (2025). Leflunomide-Mediated Immunomodulation Inhibits Lesion Progression in a Vitiligo Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146787
Vancouver
Miao F, Li X, Zhao L, Zhang S, Geng M, Ye C, et al. Leflunomide-Mediated Immunomodulation Inhibits Lesion Progression in a Vitiligo Mouse Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146787
BibTeX
@article{Miao2025,
author = {Miao, Fang and Li, Xiaohui and Zhao, Liang and Zhang, Shijiao and Geng, Mengmeng and Ye, Chuhuan and Shi, Ying and Lei, Tiechi},
title = {Leflunomide-Mediated Immunomodulation Inhibits Lesion Progression in a Vitiligo Mouse Model},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146787}
}
EUVIMED